Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Mar 30;13(4):827.
doi: 10.3390/biomedicines13040827.

Insights into Pediatric GATA2-Related MDS: Unveiling Challenges in Clinical Practice

Andra Daniela Marcu  1   2 , Ana Maria Bica  1   2 , Cristina Georgiana Jercan  1   2 , Letitia Elena Radu  1   2 , Andreea Nicoleta Serbanica  1   2 , Dumitru Jardan  3 , Andrei Colita  1   4 , Simona Olimpia Dima  1   5 , Ciprian Tomuleasa  6   7 , Alina Daniela Tanase  1   8 , Anca Colita  1   2
Affiliations
Review

Insights into Pediatric GATA2-Related MDS: Unveiling Challenges in Clinical Practice

Andra Daniela Marcu et al. Biomedicines. .

Abstract

Background:GATA2-related myelodysplastic syndrome (GATA2-MDS) is a unique predisposition syndrome with a high risk of leukemic transformation. This systematic review synthesizes current literature and presents two illustrative pediatric GATA2-MDS cases. Methods: Data retrieval from eight cohort and case-control studies provides comprehensive analysis on disease features, diagnostic complexities, management, and outcomes related to hematopoietic stem cell transplantation (HSCT) in GATA2-related myeloid malignancies. Additionally, two pediatric cases are included to exemplify clinical and therapeutic challenges in real-world setting. Results: The literature data demonstrates high incidence of monosomy 7, and recurrent infections as the most common clinical feature, followed by immunodeficiency and lymphedema. Prognosis clearly worsens with age and HSCT remains the only curative treatment. GATA2 patients undergoing HSCT experience high rates of graft versus host disease (GvHD) as well as unique neurological, thrombotic, and infectious complications. Transplant-related mortality (TRM) is linked to GvHD and infections. Post-transplant cyclophosphamide (PT/Cy) strategies seem to improve survival by reducing GvHD incidence. Overall survival (OS) remains variable across groups. The first case presents rapid disease progression to pulmonary alveolar proteinosis (PAP) and leukemic transformation, further developing severe HSCT complications. The second case addresses novel GATA2 mutation and raises concerns regarding alternative prophylactic and therapeutic strategies in transplant setting. Conclusions: Collaborative efforts aim to enhance understandings of GATA2-related myeloid malignancies and guide towards more effective management approaches.

Keywords: GATA2 mutation; GATA2-related MDS; children; hematopoietic stem cell transplantation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Figures

Figure 1
Figure 1
The PRISMA flow diagram.
See this image and copyright information in PMC

References

    1. Hahn C.N., Chong C.E., Carmichael C.L., Wilkins E.J., Brautigan P.J., Li X.C., Babic M., Lin M., Carmagnac A., Lee Y.K., et al. Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat. Genet. 2011;43:1012–1017. doi: 10.1038/ng.913. - DOI - PMC - PubMed
    1. Vicente C., Conchillo A., Garcia-Sanchez M.A., Odero M.D. The role of the GATA2 transcription factor in normal and malignant hematopoiesis. Crit. Rev. Oncol. Hematol. 2012;82:1–17. doi: 10.1016/j.critrevonc.2011.04.007. - DOI - PubMed
    1. Rajput R.V., Arnold D.E. GATA2 Deficiency: Predisposition to Myeloid Malignancy and Hematopoietic Cell Transplantation. Curr. Hematol. Malig. Rep. 2023;18:89–97. doi: 10.1007/s11899-023-00695-7. - DOI - PubMed
    1. Wlodarski M.W., Hirabayashi S., Pastor V., Stary J., Hasle H., Masetti R., Dworzak M., Schmugge M., van den Heuvel-Eibrink M., Ussowicz M., et al. Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents. Blood. 2016;127:1387–1397. doi: 10.1182/blood-2015-09-669937. - DOI - PubMed
    1. Donadieu J., Lamant M., Fieschi C., de Fontbrune F.S., Caye A., Ouachee M., Beaupain B., Bustamante J., Poirel H.A., Isidor B., et al. Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients. Haematologica. 2018;103:1278–1287. doi: 10.3324/haematol.2017.181909. - DOI - PMC - PubMed

LinkOut - more resources